Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd has notified its 34th AGM to be held on Monday, 29th September 2025 at 3:30 PM via video conferencing. Ordinary business includes adoption of FY2024-25 audited financial statements and re-appointment of Mr. Praveen J. Bafna as a director retiring by rotation. Special business covers appointment of Ms. Sathya Venkatachalam as Non-Executive Independent Director for 5 years, appointment of M/s HSPN & Associates LLP as Secretarial Auditor for FY2025-26 to FY2029-30, and revision in Executive Director Mr. Vimal D. Shah's remuneration up to Rs. 24 lakhs per annum effective 1st October 2025. Shareholders will also vote on increasing the borrowing limit to Rs. 20 crore, authorising sale/lease/disposal of company undertaking up to Rs. 10 crore, and enhancing Section 186 investment/loan limits up to Rs. 10 crore. E-voting window opens on 26th September and closes on 28th September 2025, with the cut-off date set as 22nd September 2025.
The agenda includes capital structure flexing items — higher borrowing authority (Rs. 20 crore), asset disposal power (Rs. 10 crore), and expanded investment/loan limits (Rs. 10 crore) — which signal the company may be preparing for fundraising, restructuring, or expansion. Shareholders should review the executive director pay hike and asset disposal authorisation carefully, as both require special resolution approval.